ALMS
Alumis Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$11.16
−1.79%0
Insider buys (3m)
7
Insider sells (3m)
-$534.3K
Net value (3m)
-41.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 5, 2026 | Hardiman Roy C. · officer: Chief Business & Strategy Ofcr | Sale | 2,692 | $26 |
| Aug 5, 2026 | Goldstein David M · officer: Chief Scientific Officer | Sale | 2,596 | $26 |
| Aug 5, 2026 | Drappa Jorn · officer: Chief Medical Officer | Sale | 2,447 | $26 |
| Aug 5, 2026 | Bradley Mark Christopher · officer: Chief Development Officer | Sale | 2,572 | $26 |
| Aug 5, 2026 | Schroer John R. · officer: Chief Financial Officer | Sale | 3,282 | $26 |
| Aug 5, 2026 | Pangali Sanam · officer: Chief Legal Officer | Sale | 1,364 | $26 |
| Jul 8, 2026 | Pangali Sanam · officer: Chief Legal Officer | M-Exempt | 5,000 | $5.06 |
| Jul 8, 2026 | Pangali Sanam · officer: Chief Legal Officer | Sale | 5,000 | $28 |
| Jul 2, 2026 | Srivastava Sapna · director | A-Award | 3,553 | $0.00 |
| Jul 2, 2026 | Yao Zhengbin · director | A-Award | 3,553 | $0.00 |
| Jul 2, 2026 | TETRAULT LYNN A. · director | A-Award | 15,528 | $28 |
| Jul 2, 2026 | TETRAULT LYNN A. · director | A-Award | 3,553 | $0.00 |
| Jul 2, 2026 | AKKARAJU SRINIVAS · director | A-Award | 15,528 | $28 |
| Jul 2, 2026 | AKKARAJU SRINIVAS · director | A-Award | 3,553 | $0.00 |
| Jul 2, 2026 | Machado Patrick · director | A-Award | 15,528 | $28 |
| Jul 2, 2026 | Machado Patrick · director | A-Award | 3,553 | $0.00 |
| Jul 2, 2026 | Srivastava Sapna · director | A-Award | 15,528 | $28 |
| Jul 2, 2026 | Yao Zhengbin · director | A-Award | 15,528 | $28 |
| May 27, 2026 | Drappa Jorn · officer: Chief Medical Officer | M-Exempt | 15,535 | $5.06 |
| May 27, 2026 | Drappa Jorn · officer: Chief Medical Officer | M-Exempt | 11,317 | $8.84 |
| Jan 28, 2026 | Schroer John R. · officer: Chief Financial Officer | A-Award | 202,225 | $26 |
| Jan 28, 2026 | Pangali Sanam · officer: Chief Legal Officer | A-Award | 186,200 | $26 |
| Jan 28, 2026 | Drappa Jorn · officer: Chief Medical Officer | A-Award | 221,450 | $26 |
| Jan 28, 2026 | Bradley Mark Christopher · officer: Chief Development Officer | A-Award | 190,225 | $26 |
| Jan 28, 2026 | Hardiman Roy C. · officer: Chief Business & Strategy Ofcr | A-Award | 190,875 | $26 |
| Jan 28, 2026 | Babler Martin · director, officer: President, CEO and Chairman | A-Award | 745,875 | $26 |
| Jan 28, 2026 | Goldstein David M · officer: Chief Scientific Officer | A-Award | 216,675 | $26 |
| Jan 13, 2026 | AKKARAJU SRINIVAS · director | Purchase | 588,235 | $17 |
| Jan 12, 2026 | Tananbaum James B. · director, 10 percent owner: | Purchase | 294,117 | $17 |
| Jan 12, 2026 | Foresite Labs, LLC · 10 percent owner | Purchase | 117,647 | $17 |
Institutional positioning
13F filings over the trailing two quarters
New 120Increased 138Reduced 100Sold out 22
| Filer | Action | Shares | Filed |
|---|---|---|---|
| AyurMaya Capital Management Company, LP | Unchanged | 15,139,707 | Aug 13, 2026 |
| BlackRock, Inc. | Increased | 8,218,151 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 7,170,868 | May 13, 2026 |
| DEEP TRACK CAPITAL, LP | New Position | 6,772,595 | May 15, 2026 |
| FMR LLC | Increased | 6,769,170 | Aug 13, 2026 |
| Deep Track Capital, LP | Reduced | 6,348,558 | Aug 14, 2026 |
| Samsara BioCapital, LLC | Unchanged | 6,345,219 | Aug 14, 2026 |
| SAMSARA BIOCAPITAL, LLC | Increased | 6,345,219 | May 15, 2026 |
| Foresite Capital Management V, LLC | Unchanged | 5,896,995 | Aug 14, 2026 |
| FORESITE CAPITAL MANAGEMENT V, LLC | Increased | 5,896,995 | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 5,199,838 | Aug 14, 2026 |
| venBio Partners LLC | Unchanged | 4,528,408 | Aug 14, 2026 |
| VENBIO PARTNERS LLC | Reduced | 4,528,408 | May 15, 2026 |
| Foresite Capital Management VI LLC | Unchanged | 4,247,670 | Aug 14, 2026 |
| FORESITE CAPITAL MANAGEMENT VI LLC | Unchanged | 4,247,670 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 5, 2026